{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T02:29:32Z","timestamp":1769999372799,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"iNOVA4Health Research Unit","award":["LISBOA-01-0145-FEDER-007344"],"award-info":[{"award-number":["LISBOA-01-0145-FEDER-007344"]}]},{"name":"Associa\u00e7\u00e3o de Endocrinologia Oncol\u00f3gica"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s40618-018-0947-4","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T07:49:05Z","timestamp":1536220145000},"page":"527-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The efficacy of HRAS and CDK4\/6 inhibitors in anaplastic thyroid cancer cell lines"],"prefix":"10.1007","volume":"42","author":[{"given":"S.","family":"Lopes-Ventura","sequence":"first","affiliation":[]},{"given":"M.","family":"Pojo","sequence":"additional","affiliation":[]},{"given":"A. T.","family":"Matias","sequence":"additional","affiliation":[]},{"given":"M. M.","family":"Moura","sequence":"additional","affiliation":[]},{"given":"I. J.","family":"Marques","sequence":"additional","affiliation":[]},{"given":"V.","family":"Leite","sequence":"additional","affiliation":[]},{"given":"B. M.","family":"Cavaco","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"issue":"3","key":"947_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5306\/wjco.v2.i3.150","volume":"2","author":"F Perri","year":"2011","unstructured":"Perri F et al (2011) Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2(3):150\u2013157","journal-title":"World J Clin Oncol"},{"key":"947_CR2","doi-asserted-by":"publisher","first-page":"542358","DOI":"10.1155\/2011\/542358","volume":"2011","author":"G Nagaiah","year":"2011","unstructured":"Nagaiah G et al (2011) Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011:542358","journal-title":"J Oncol"},{"issue":"10","key":"947_CR3","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/sj.bjc.6605340","volume":"101","author":"JM Pita","year":"2009","unstructured":"Pita JM et al (2009) Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer 101(10):1782\u20131791","journal-title":"Br J Cancer"},{"issue":"3","key":"947_CR4","doi-asserted-by":"publisher","first-page":"E497","DOI":"10.1210\/jc.2013-1512","volume":"99","author":"JM Pita","year":"2014","unstructured":"Pita JM et al (2014) Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas. J Clin Endocrinol Metab 99(3):E497\u2013E507","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"947_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nrclinonc.2016.19","volume":"13","author":"KC Bible","year":"2016","unstructured":"Bible KC, Ryder M (2016) Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol 13(7):403\u2013416","journal-title":"Nat Rev Clin Oncol"},{"key":"947_CR6","doi-asserted-by":"publisher","first-page":"384213","DOI":"10.4061\/2011\/384213","volume":"2011","author":"I Legakis","year":"2011","unstructured":"Legakis I, Syrigos K (2011) Recent advances in molecular diagnosis of thyroid cancer. J Thyroid Res 2011:384213","journal-title":"J Thyroid Res"},{"issue":"11","key":"947_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D (2011) RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11(11):761\u2013774","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"947_CR8","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1182\/blood-2011-02-334870","volume":"118","author":"H Ding","year":"2011","unstructured":"Ding H et al (2011) Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood 118(18):4872\u20134881","journal-title":"Blood"},{"issue":"1","key":"947_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3324\/haematol.2013.087734","volume":"99","author":"H Ding","year":"2014","unstructured":"Ding H et al (2014) Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica 99(1):60\u201369","journal-title":"Haematologica"},{"issue":"1","key":"947_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/jcp.25411","volume":"232","author":"T Tanaka","year":"2017","unstructured":"Tanaka T et al (2017) Low-dose farnesyltransferase inhibitor suppresses HIF-1alpha and snail expression in triple-negative breast cancer MDA-MB-231 cells in vitro. J Cell Physiol 232(1):192\u2013201","journal-title":"J Cell Physiol"},{"issue":"9","key":"947_CR11","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/pbc.25041","volume":"61","author":"BC Widemann","year":"2014","unstructured":"Widemann BC et al (2014) Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer 61(9):1598\u20131602","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"947_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11060-015-1860-8","volume":"124","author":"S Ken","year":"2015","unstructured":"Ken S et al (2015) Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I\u2013II trial of radiotherapy\/tipifarnib combination. J Neurooncol 124(3):465\u2013473","journal-title":"J Neurooncol"},{"issue":"5","key":"947_CR13","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1158\/1535-7163.MCT-07-2422","volume":"7","author":"D Hong","year":"2008","unstructured":"Hong D et al (2008) Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib\/tipifarnib. Mol Cancer Ther 7(5):1001\u20131006","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"947_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1210\/jc.2010-1899","volume":"96","author":"DS Hong","year":"2011","unstructured":"Hong DS et al (2011) Inhibition of the Ras\/Raf\/MEK\/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96(4):997\u20131005","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"947_CR15","doi-asserted-by":"publisher","first-page":"7061","DOI":"10.1158\/1078-0432.CCR-09-1241","volume":"15","author":"DS Hong","year":"2009","unstructured":"Hong DS et al (2009) Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15(22):7061\u20137068","journal-title":"Clin Cancer Res"},{"issue":"6","key":"947_CR16","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1210\/jc.2012-3623","volume":"98","author":"F Frasca","year":"2013","unstructured":"Frasca F et al (2013) Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. J Clin Endocrinol Metab 98(6):2502\u20132512","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"947_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.trsl.2014.06.005","volume":"164","author":"Z Milosevic","year":"2014","unstructured":"Milosevic Z et al (2014) Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl Res 164(5):411\u2013423","journal-title":"Transl Res"},{"issue":"7","key":"947_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary B, Finn RS, Turner NC (2016) Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol 13(7):417\u2013430","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"947_CR19","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/ijc.25511","volume":"127","author":"P Ozenne","year":"2010","unstructured":"Ozenne P et al (2010) The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 127(10):2239\u20132247","journal-title":"Int J Cancer"},{"issue":"6","key":"947_CR20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djs002","volume":"104","author":"PJ Roberts","year":"2012","unstructured":"Roberts PJ et al (2012) Multiple roles of cyclin-dependent kinase 4\/6 inhibitors in cancer therapy. J Natl Cancer Inst 104(6):476\u2013487","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"947_CR21","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry DW et al (2004) Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3(11):1427\u20131438","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"947_CR22","doi-asserted-by":"publisher","first-page":"e88219","DOI":"10.1371\/journal.pone.0088219","volume":"9","author":"RT Williams","year":"2014","unstructured":"Williams RT et al (2014) Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth. PLoS One 9(2):e88219","journal-title":"PLoS One"},{"issue":"5","key":"947_CR23","doi-asserted-by":"publisher","first-page":"e0177019","DOI":"10.1371\/journal.pone.0177019","volume":"12","author":"T Tanaka","year":"2017","unstructured":"Tanaka T et al (2017) The efficacy of the cyclin-dependent kinase 4\/6 inhibitor in endometrial cancer. PLoS One 12(5):e0177019","journal-title":"PLoS One"},{"issue":"2","key":"947_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","volume":"18","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT et al (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 18(2):568\u2013576","journal-title":"Clin Cancer Res"},{"issue":"20","key":"947_CR25","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","volume":"119","author":"JP Leonard","year":"2012","unstructured":"Leonard JP et al (2012) Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119(20):4597\u20134607","journal-title":"Blood"},{"issue":"7","key":"947_CR26","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamaoncol.2016.0264","volume":"2","author":"MA Dickson","year":"2016","unstructured":"Dickson MA et al (2016) Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol 2(7):937\u2013940","journal-title":"JAMA Oncol"},{"issue":"1","key":"947_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13058-016-0721-5","volume":"18","author":"RS Finn","year":"2016","unstructured":"Finn RS et al (2016) Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1\/TRIO-18. Breast Cancer Res 18(1):67","journal-title":"Breast Cancer Res"},{"issue":"20","key":"947_CR28","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925\u20131936","journal-title":"N Engl J Med"},{"issue":"11","key":"947_CR29","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1210\/jc.2008-1102","volume":"93","author":"RE Schweppe","year":"2008","unstructured":"Schweppe RE et al (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93(11):4331\u20134341","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"947_CR30","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.18632\/oncotarget.3150","volume":"6","author":"M Pojo","year":"2015","unstructured":"Pojo M et al (2015) A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. Oncotarget 6(10):7657\u20137674","journal-title":"Oncotarget"},{"issue":"4","key":"947_CR31","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1007\/s13277-015-4385-z","volume":"37","author":"LS Silva","year":"2016","unstructured":"Silva LS et al (2016) STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment. Tumour Biol 37(4):5385\u20135395","journal-title":"Tumour Biol"},{"issue":"2","key":"947_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4161\/spmg.1.2.16606","volume":"1","author":"DD Mruk","year":"2011","unstructured":"Mruk DD, Cheng CY (2011) Enhanced chemiluminescence (ECL) for routine immunoblotting: an inexpensive alternative to commercially available kits. Spermatogenesis 1(2):121\u2013122","journal-title":"Spermatogenesis"},{"issue":"3","key":"947_CR33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s12020-016-1080-9","volume":"54","author":"S Latteyer","year":"2016","unstructured":"Latteyer S et al (2016) Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine 54(3):733\u2013741","journal-title":"Endocrine"},{"issue":"2","key":"947_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11912-007-0014-3","volume":"9","author":"WR Cornett","year":"2007","unstructured":"Cornett WR et al (2007) Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 9(2):152\u2013158","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"947_CR35","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa I et al (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126(3):1052\u20131066","journal-title":"J Clin Invest"},{"issue":"26","key":"947_CR36","doi-asserted-by":"publisher","first-page":"42613","DOI":"10.18632\/oncotarget.17300","volume":"8","author":"V Tiedje","year":"2017","unstructured":"Tiedje V et al (2017) NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. Oncotarget 8(26):42613\u201342620","journal-title":"Oncotarget"},{"issue":"8","key":"947_CR37","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","volume":"24","author":"JW Kunstman","year":"2015","unstructured":"Kunstman JW et al (2015) Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet 24(8):2318\u20132329","journal-title":"Hum Mol Genet"},{"issue":"4","key":"947_CR38","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2000.18.4.927","volume":"18","author":"J Zujewski","year":"2000","unstructured":"Zujewski J et al (2000) Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18(4):927\u2013941","journal-title":"J Clin Oncol"},{"issue":"4","key":"947_CR39","first-page":"415","volume":"1","author":"X Thomas","year":"2007","unstructured":"Thomas X, Elhamri M (2007) Tipifarnib in the treatment of acute myeloid leukemia. Biologics 1(4):415\u2013424","journal-title":"Biologics"},{"issue":"9","key":"947_CR40","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1158\/1078-0432.CCR-08-3004","volume":"15","author":"K Weide van der","year":"2009","unstructured":"van der Weide K et al (2009) Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34\u2009+\u2009acute myeloid leukemia samples. Clin Cancer Res 15(9):3076\u20133083","journal-title":"Clin Cancer Res"},{"issue":"1","key":"947_CR41","first-page":"131","volume":"61","author":"DW End","year":"2001","unstructured":"End DW et al (2001) Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61(1):131\u2013137","journal-title":"Cancer Res"},{"issue":"25","key":"947_CR42","doi-asserted-by":"publisher","first-page":"11501","DOI":"10.1073\/pnas.1001613107","volume":"107","author":"WR Wiedemeyer","year":"2010","unstructured":"Wiedemeyer WR et al (2010) Pattern of retinoblastoma pathway inactivation dictates response to CDK4\/6 inhibition in GBM. Proc Natl Acad Sci USA 107(25):11501\u201311506","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"947_CR43","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","volume":"17","author":"GE Konecny","year":"2011","unstructured":"Konecny GE et al (2011) Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer. Clin Cancer Res 17(6):1591\u20131602","journal-title":"Clin Cancer Res"},{"issue":"5","key":"947_CR44","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS et al (2009) PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11(5):R77","journal-title":"Breast Cancer Res"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0947-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-018-0947-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0947-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T22:29:11Z","timestamp":1693866551000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-018-0947-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["947"],"URL":"https:\/\/doi.org\/10.1007\/s40618-018-0947-4","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]},"assertion":[{"value":"19 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethical Committee of Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG). This article does not contain any studies with human subjects or animal experiments performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was previously obtained from patients to establish <i>in-house<\/i> derived cell lines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}